Cabozantinib for Non-Small Cell Lung Cancer
Trial Summary
What is the purpose of this trial?
The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity. A phase II study looks at how effective a medication is at treating a specific type of cancer and collects information on the side effects of the study treatment. RET, ROS1, or NTRK fusion or increased MET or AXL activity gene leads to lung cancer cell growth. Cabozantinib is an oral medicine that inhibits of RET, ROS1, NTRK, MET, and AXL. In addition, this drug interferes with other cell pathways that also cause cancer cells to grow, form new blood vessels, and spread to other organs of the body. The goal of using cabozantinib is to shrink the cancer and to prevent it from growing Cabozantinib has been studied and shown to cause cancer shrinkage in other cancers such as medullary thyroid cancer and prostate cancer. We thus have a good idea of what side-effects it causes and can anticipate them.
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications, but it does mention that you cannot have taken any systemic anticancer agents within 3 weeks of starting the study. If you are on anticoagulants, you may need to adjust your treatment, as only low-dose aspirin and certain types of heparin are allowed.
What data supports the effectiveness of the drug Cabozantinib for treating non-small cell lung cancer?
Is Cabozantinib generally safe for humans?
Cabozantinib, also known as Cabometyx, has been studied for various conditions, and while specific safety data for non-small cell lung cancer isn't provided here, it has been used in other cancers with a known safety profile. Like many cancer treatments, it may have side effects, so it's important to discuss potential risks with your doctor.678910
How is the drug Cabozantinib unique for treating non-small cell lung cancer?
Research Team
Alexander Drilon, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
Adults with advanced non-small cell lung cancer that is metastatic or unresectable and have specific genetic changes (RET, ROS1, NTRK fusions, MET or AXL overexpression/amplification/mutation). Must be able to perform daily activities well (Karnofsky >70%), have good organ function, not pregnant, agree to use contraception. Excludes those with recent significant illnesses/treatments or known allergies to cabozantinib.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive cabozantinib to assess its effects on tumors with RET, ROS1, or NTRK fusion, or increased MET or AXL activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cabozantinib (Tyrosine Kinase Inhibitor)
Cabozantinib is already approved in Canada, Japan for the following indications:
- Renal cell carcinoma
- Hepatocellular carcinoma
- Renal cell carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Exelixis
Industry Sponsor